Evidence map›Paper›PMID 33580440›Full record

ReviewCurrent topics in behavioral neurosciences2022

GABA

Warren B Logge, Kirsten C Morley, Paul S Haber

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in behavioral neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Trial
  3. GABA-independent activation of GABANature communications · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Warren B LoggeDiscipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia. warren.logge@sydney.edu.au.
Kirsten C MorleyDiscipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia.
Paul S HaberDiscipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia.
University of Sydney · AURoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Harmful alcohol use and alcohol use disorders (AUD) result in major health and community burden worldwide, yet treatment options are limited. Novel pharmacotherapies are urgently required, and treatments involving GABA

Indexed as

AlcoholismSubstance Withdrawal SyndromeBaclofenGABA-B Receptor AgonistsHumansReceptors, GABA-BBaclofenGABA-B Receptor AgonistsReceptors, GABA-BAlcohol use disorderAlcohol withdrawalBaclofenNeuroimagingPharmacotherapyPsychophysiologyRandomised controlled trialTreatment

Identifiers

PMID33580440
OpenAlexW3127793805

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.